

Cannabidiol in Epilepsy:

The indications, mechanisms and beyond

Apasri Lusawat M.D. Pediatric Neurology Department Neurological Institute of Thailand



Major studies : CBD in epilepsy

TABLE 1 | Major studies about CBD in the treatment of epilepsy.

Study	Number of patients		
Devinsky et al. (22) - TRE OL	214		
Hess et al. (23) - Tuberous sclerosis OL	18		
Devinsky et al. (24) - Dravet RCT	61		
Thiele et al. (26) - LG RCT	86		
Devinsky et al. (25) - LG RCT 20 mg/kg	76		
Thiele et al. (30) - LG OL	366		
Devinsky et al. (31) - Dravet OL	264		
Szaflarski et al. (32) - TRE OL	607		

TRE, treatment-resistant epilepsy; OL, open label; LG, Lennox-Gastaut; RCT, randomized controlled trial.





FIGURE 1 | Comparison of efficacy in the main studies. TRE, treatment-resistant epilepsy; OL, open label; LG, Lennox-Gastaut; RCT, randomized controlled trial. Adapted from (12).



Cannabidiol in Epilepsy, 3 RCT



Perruca E. Journal of Epilepsy Research Vol. 7, No. 2, 2017









AEs Reported in the Open-Label Extension Study Data from Devinsky et al ¹ and Thiele et al ² Dose CBD 20-30 mg/k/d

	DS n=264	LGS n=366		DS n=264	LGS n=366
All-causality AEs, n (%) AEs leading to withdrawal, n (%)	246 (93.2) 19 (7.2)	337 (92.1) 35 (9.6)	SAEs reported in >1% patients, n (%) Status epilepticus	29 (11.0)	26 (7.1)
AEs reported in >10% of patients, n (%)			Convulsion	13 (4.9)	20 (5.5)
Diarrhea	91 (34.5)	98 (26.8)	Pyrexia	10 (3.8)	
Pyrexia	72 (27.3)	69 (18.3)	Pneumonia	7 (2.7)	9 (2.5)
Decreased appetite	67 (25.4)	65 (17.8)	AST increased	5 (1.9)	6 (1.6)
Somnolence	65 (24.6)	86 (23.5)	ALT increased		6 (1.6)
Nasopharyngitis	41 (15.5)		Hepatic enzyme increased		4 (1.1)
Convulsion	40 (15.2)	78 (21.3)	Pneumonia aspiration		6 (1.6)
Vomiting	37 (14.0)		Dehydration	4 (1.5)	0 (0)
Upper respiratory tract infection	36 (13.6)	53 (14.5)	Influenza		
Status epilepticus	29 (11.0)			4 (1.5)	
Fatigue	27 (10.2)		GTCSs	4 (1.5)	
SAEs, n (%)	77 (29.2)	94 (25.7)	Diarrhea	3 (1.1)	

Abbreviations: AE, adverse event; DS, Dravet syndrome; GTCSs, generalized tonic-clonic seizures; LGS, Lennox-Gastaut syndrome; SAE, serious adverse event.

1.Epilepsia. 2019;60(2):294–302

2. Epilepsia. 2019;60(3):419-428

Table from Neuropsychiatric Disease and Treatment 2020:16




Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex : RCT



TSC +DRE 224 cases : CBD 25 mkd : 50 mkd : placebo x 16 weeks

Figure 2. Seizure Outcomes During the Treatment Period



Cannabidiol significantly reduced TSC-associated seizures compared with placebo. The 25-mg/kg/day dosage had a better safety profile than the 50-mg/kg/day dosage.

JAMA Neurol. 2021;78(3):285-292.

Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions <u>Beyond</u> Dravet Syndrome and Lennox–Gastaut Syndrome



<u>**Results**</u> 42 of 57 studies for the review. Included both pediatric and adult age.

- Across the trials, purified CBD was administered at dosages up to 50 mg/kg/day.
- RCT in TSC showed efficacy in greater seizure reduction than placebo in treatment period.
- Open-label studies suggested the effectiveness of CBD in the treatment of children and adults presenting with other epilepsy syndromes than those addressed by regulatory trials, including CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes, SYNGAP1 encephalopathy, and epilepsy with myoclonic absences.
- The most common adverse events observed during treatment with CBD included somnolence, decreased appetite, diarrhea, and increased serum aminotransferases.

<u>Conclusions</u> The currently available data suggest that response to treatment with a highly purified, plant-derived CBD oil based solution can be seen in patients across a broad range of epilepsy disorders and etiologies. The existing evidence can provide preliminary support for additional research.

CNS Drugs 2021, 35:265-281



Why should cannabis be used in epilepsy?



- Unmet need and last resort for severe DRE
- New mechanism of action in antiseizure effect
- Improve other brain function/anti-epileptogenesis /neuroprotective effect ?




Endocannabinoid System (ECS)



- The ECS is a key modulatory system involving the cannabinoid receptor 1 (CB1) and 2 (CB2)
 - CB1 presynaptic in olfactory bulb, C.cortex, striatum, hippocampus
 - CB2 immune cell & hematopoietic cell, brain stem neuron
- The ECS plays an important role in the neuroprotection of acute neurological diseases, such as epilepsy, as well as chronic neurodegenerative diseases such as Parkinson's disease
- Endocannabinoids (AEA, 2AG) diffuse retrogradely to a presynaptic bouton and bind to receptors reducing the likelihood of release of the excitatory and inhibitory neurotransmitters







Proposed mechanism of CBD in epilepsy.



CBD reduces neuronal excitability through functional antagonism of GPR55 receptors, desensitization of TRPV1 receptors and inhibition of adenosine transport





Biosynthetic pathway of major phytocannabinoids





Figure 1. Biosynthetic pathway of major phytocannabinoids.

สถาบันประสาทวิทยา: โรงพยาบาลเฉพาะทางโรคสมองและระบบประสาทไขสันหลัง

สถาบันประสาทวิทยา

Phytocannabinoids : anticonvulsant activity





Pharmaceuticals 2020, 13, 174

Figure 2. Structures of nine phytocannabinoids showing anticonvulsant activity; Δ^9 -tetrahydrocannabinol (Δ^9 -THC), Δ^8 -tetrahydrocannabinol (Δ^8 -THC), Δ^9 -tetrahydrocannabutol (Δ^9 -THCB), Δ^9 -tetrahydrocannabivarin (THCV), cannabidiol (CBD), cannabidivarin (CBDV), cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG).



CBDV, \triangle 9-THCV and CBG have

- Anticonvulsant characteristics combined with favorable side-effect profiles
- Clear neuroprotective/neurogenerative characteristic has been identified

Int. J. Environ. Res. Public Health 2021, 18, 3993



Cannabidivarin (CBDV)



Direct CBD analogue derived from cannabigerovarin

- CBDV inhibits the reuptake of AEA and 2-AG at micro- and nanomolar concentrations, respectively
- CBDV has been shown to dose dependently activate these channels (TRPV1, TRPV2 and TRPA1) makes it a novel target for treating epilepsy symptoms.
- In a randomised block design participants received 400-mg CBDV over a treatment period of 14 days. It was observed that CBDV did not significantly reduce seizure instances.
- Suspected inefficacy of purified CBDV vs CBDV-rich ??

Neuropsychiatr. Dis. Treat. 2020, 16, 381–396





- CBDV isomerises into Δ^9 -THCV \rightarrow potential Rx epilepsy
- Δ⁹-THCV exhibits antagonist actions at both CB1 and CB2 receptors : inhibiting seizure like activity through a non-CB1 receptor-mediated mechanism
- Little evidence is currently available to conclude that Δ⁹-THCV is not effective in treating the symptoms of epilepsy

J. Cannabis Res. 2020, 2, 1–6.



Cannabigerol (CBG)



Major phytocannabinoids present in Cannabis sativa

- Agonist for both CB1 and CB2 receptors
- Agonist of TRPA1, TRPV1, TRPV2 channels, antagonist of TRPM8 channels.
- Endocannabinoid reuptake inhibitor
- Antagonist of serotonin receptors, 5-HT2A receptor signalling → control of neuronal excitability through GABAergic, monoaminergic & glutamatergic neurotransmission
- CBG activates α 2-adrenoreceptors and blocks activity at 5-HT1A receptors \rightarrow anticonvulsant potential
- Lack of pre-clinical research specifically analysing CBG's efficacy as an anticonvulsant
- Begin investigating CBG- potential enhancer of other compounds, 'entourage effect'

Int. J. Environ. Res. Public Health 2021, 18, 3993



Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.




- By regulating the biochemical synthesis and degradation of ECS (2-AG and AEA), as well as AEA reuptake→anti-seizure effects in pre-clinical acute models of seizure
- Both direct (i.e. CB1R agonism) and indirect approaches (inhibition of endocannabinoid catabolism) can hinder epileptogenesis in animal models
- Cannabinoids \rightarrow **neuroprotective** candidates with seizures-induced brain injury.
 - \rightarrow inhibition of excitotoxic insults
 - →inhibition of free radical-induced oxidative damage, regulation of PI3K/Akt/GSK-3 signaling pw, augmentation of microcirculation in brain +protection of the microglial function



Cannabinoids & SZ, Epileptogenesis, Neuroprotection





- Pre-clinical animal models of seizures, epilepsy, and epileptogenesis. Compiled data from synthetic and phytocannabinoids in 181 total animal models of
 - A. Acute models of seizures and epilepsy.
 - B. Chronic models of epileptogenesis.
- Pre-clinical interventions were subdivided into
 - (1) Modulators of the Endocannabinoid System ("eCB")
 - (2) CB1/CB2R Agonists,
 - (3) CB1/CB2R Antagonists,
 - (4) D9THC/THCV,
 - (5) CBD/CBDV.

Epilepsy Behav. 2017,70(Pt B): 319–327





Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis



Pamplona ,et al.2018

Effect	CBD purified	CBD enriched	Difference
Sz improved	36%	71%	P < 0.0001
>50%sz reduction	42%	37%	P =NS
Sz free	~10%	~10%	P= NS
Mean dose	27.1 mg/kg/d	6.1 mg/kg/d	22.5% diff
Mild ADR	158/216, 76%	148/447, 33%	P < 0.0001
Severe ADR	41/155, 26%	23/328, 7%	P < 0.0001

Treatment references	Medical center	Study design	Patients	Age (year)	Duration
CBD pure (6)	Langone Med. Center NY Univ. (USA)	Prospective medical record	137	10.5 year (1–30)	3 months
CBD pure (7)	Child Neurology, Child Hosp. Philadelphia (USA)	Prospective medical record	7	NR	12 months
CBD pure (8)	Pediatric Epilepsy, Mass. Gen. Hospital-Harvard (USA)	Prospective medical record	13	10.8 year	2 months
CBD pure (9)	Pediatric Epilepsy, Mass. Gen. Hospital-Harvard (USA)	Prospective medical record	18	ATA meta-analysis :	nactivo nt curvov
CBD pure (10)	Langone Med. Center NY Univ. (USA)	Prospective medical record	48	 CBD rich : retrospective, pt survey CBD pure: prospective 	
CBD-rich extract (11)	Neurology, Stanford (USA)	Parent survey (online)	19	(2–16)	
CBD-rich extract (12)	Pediatric Neurology, Univ. Calif. Los Angeles-UCLA (USA)	(online) Parent survey (online)	117	6 year (0.4–NR)	6.8 months
CBD-rich extract (28)	Pediatrics and Neurology, Univ. Colorado (USA)	Retrospective medical record	75	7.3 year (0.5–18)	5.6 months
CBD-rich extract (13)	Pediatric Neurology, Sheba Medical Center (Israel)	Retrospective medical record	74	~10 year (1–18)	6 months
CBD-rich extract (14)	Inst. Tec. Est. Sup. Monterrey (Mexico)	Parent survey (online)	53	~9.4 year (0.8–18)	4.2 months (1–12)
CBD-rich extract (15)	Pediatrics and Neurology, Univ, Colorado (USA)	Retrospective medical record	119	7.5 year (0.1–18)	11.7 months
	สถาบันเ	<u> </u>	ุ่มยาบาลเฉพาะ	ทางไรคสมองและระ	บบประสาทไขสนห




Efficacy and safety of CBD enriched in pediatric drug resistant epilepsy in Observational Data Meta-analysis vs Thailand



Effect	CBD purified	CBD enriched	Thai CBD enriched
Total cases	223	447	14
Duration of Rx (mo)	3-12	4-12	12
Convulsive Sz improved	36%	71%	58%
>50% SR responder	42%	37%	50%
Sz free	~10%	~10%	14%
Mean dose (mg/k/d)	27.1	6.1	5.6
Mild ADR	158/216, 76%	148/447, 33%	10/14, 71%
Severe ADR	41/155, 26%	23/328, 7%	6/14, 42%
Study	Meta-an Pamplona ,e	Retrospective Cohort Lusawat, et al 2021	



Gaps in knowledge: CBD for epilepsy in adults, long-term safety, and access to CBD



- Cannabis use associated with executive dysfunction \rightarrow impair worker and driver safety
- Long-term cognitive, behavioral, and psychiatric side effects are another concern
- No clinical data of teratogenicity of CBD→ prenatal cannabis is associated with low birth weight
- For the same CBD plasma level, differences in seizure improvement do not depend on age
 - Plasma levels may be a strategy to guide CBD doses
- Can be defined as necessity to 1 dose by at least 30% or a response >30%.reduction
- The mean time until the appearance of tolerance was found to be 7 months
- The long-term risks and efficacy of CBD use are unknown
- Cost is prohibitive for some patients

Front. Neurol. 2020, 11:531939



Further reading



- Highly Purifed Cannabidiol for Epilepsy Treatment : A Systematic Review of Epileptic Conditions Beyond
 Dravet Syndrome and Lennox–Gastaut Syndrome CNS Drugs 2021, 35:265–281
- Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex A Placebo-Controlled Randomized Clinical Trial *JAMA Neurol. 2021;78(3):285-292.*
- Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps Front. Neurol. 2020, 11:531939
- Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and Epilepsy *Pharmaceuticals 2020, 13, 174*
- Phytocannabinoids other than CBD in epilepsy Int. J. Environ. Res. Public Health 2021, 18, 3993
- Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis *Front. Neurol.2018, 9:759*





THANK YOU

สถาบันประสาทวิทยา

Neurological Institute of Thailand

โรงพยาบาลเฉพาะทางโรคสมองและระบบประสาทไขสันหลัง